{"nctId":"NCT01507896","briefTitle":"BAX 326 Surgery Study in Hemophilia B Patients","startDateStruct":{"date":"2011-12-19","type":"ACTUAL"},"conditions":["Hemophilia B"],"count":30,"armGroups":[{"label":"BAX326 in Surgery","type":"EXPERIMENTAL","interventionNames":["Biological: Recombinant factor IX"]}],"interventions":[{"name":"Recombinant factor IX","otherNames":["BAX326","RIXUBIS"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Participant and/or legal representative has/have voluntarily provided signed informed consent.\n* Participant has severe (FIX level \\< 1%) or moderately severe (FIX level 1-2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory.\n* Participant requires surgery\n* Participant has previously been treated with plasma-derived and/or recombinant FIX concentrate(s) for a minimum of 150 exposure days\n* Participant has no evidence of a history of FIX inhibitors\n* Participant is immunocompetent as evidenced by a CD4 count ≥ 200 cells/mm3.\n* Participant is human immunodeficiency (HIV) negative or is HIV+ with a viral load \\< 200 particles/μL \\~ \\< 400,000 copies/mL.\n\nMain Exclusion Criteria:\n\n* Participant has a history of FIX inhibitors with a titer ≥ 0.6 Bethesda Units (BU) (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening.\n* Participant has a detectable FIX inhibitor at screening, with a titer ≥0.6 Bethesda Units (BU) as determined by the Nijmegen modification of the Bethesda assay in the central laboratory.\n* Participant has a history of allergic reaction or evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).\n* Known hypersensitivity to hamster proteins or recombinant furin.\n* Evidence of an ongoing or recent thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC).\n* Abnormal renal function\n* Severe chronic liver disease\n* Active hepatic disease with ALT or AST levels \\> 5 times the upper limit of normal.\n* Diagnosis of an iherited or acquired hemostatic defect other than hemophilia B.\n* Platelet count \\< 100,000/mL.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intraoperative Hemostatic Efficacy","description":"Assessment by the operating surgeon on a 4 point ordinal scale (according to the definitions provided below): - Excellent: Intraoperative blood loss was less than or equal to that expected for the type of procedure performed in a hemostatically normal participant (≤ 100% ) - Good: Intraoperative blood loss was up to 50% more than expected for the type of procedure performed in a hemostatically normal participant (101 - 150%) - Fair: Intraoperative blood loss was more than 50% of that expected for the type of procedure performed in a hemostatically normal participant (\\> 150%) - None: Uncontrolled hemorrhage that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of Factor IX concentrate","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Actual Intraoperative Blood Loss","description":"Actual intraoperative blood loss was determined by the drainage volume, if a drain was placed, and the estimated blood loss into swabs and towels during the procedure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191.1","spread":"354.1"},{"groupId":"OG001","value":"344.9","spread":"420.1"},{"groupId":"OG002","value":"1.2","spread":"1.1"}]}]}]},{"type":"PRIMARY","title":"Actual Intraoperative Blood Loss Compared to Average and Maximum Blood Loss Predicted Preoperatively by the Operating Surgeon","description":"Predicted average/maximum blood loss minus actual blood loss. Prior to the surgery, the surgeon predicted the estimated volume (mL) of the expected average and maximum blood loss for the planned surgical intervention in a hemostatically normal individual of the same sex, age, and stature as the study participant for the intraoperative period.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.0","spread":"158.9"},{"groupId":"OG001","value":"-50.9","spread":"213.0"},{"groupId":"OG002","value":"2.4","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128.3","spread":"260.8"},{"groupId":"OG001","value":"222.0","spread":"323.7"},{"groupId":"OG002","value":"12.5","spread":"24.5"}]}]}]},{"type":"PRIMARY","title":"Postoperative Hemostatic Efficacy at Drain Removal","description":"The postoperative hemostatic efficacy was to be assessed by the operating surgeon according to the following criteria (4-point ordinal scale): - Excellent: Volume in drain was less than or equal than that expected for the type of procedure performed in a hemostatically normal participant (≤ 100% ) - Good: Volume in drain was up to 50% more than expected for the type of procedure performed in a hemostatically normal participant (101% - 150%) - Fair: Volume in drain was more than 50% of that expected for the type of procedure performed in a hemostatically normal participant (\\> 150%) - None: Uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of Factor IX concentrate","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Postoperative Hemostatic Efficacy at Postoperative Day 3","description":"Assessment by the operating surgeon on a 4 point ordinal scale: - Excellent: Postoperative hemostasis achieved with BAX326 was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal participant - Good: Postoperative hemostasis achieved with BAX326 was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal participant - Fair: Postoperative hemostasis with BAX326 was clearly less than optimal for the type of procedure performed but was maintained without the need to change the Factor IX concentrate - None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of Factor IX concentrate","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Postoperative Hemostatic Efficacy on Day of Discharge","description":"Assessment by the operating surgeon on a 4 point ordinal scale: - Excellent: Postoperative hemostasis achieved with BAX326 was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal participant - Good: Postoperative hemostasis achieved with BAX326 was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal participant - Fair: Postoperative hemostasis with BAX326 was clearly less than optimal for the type of procedure performed but was maintained without the need to change the Factor IX concentrate - None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of Factor IX concentrate","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Actual Postoperative Blood Loss","description":"Postoperative blood loss was based on the drainage fluid and was only assessed for participants who had a drain placed during surgery.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"603.6","spread":"388.7"}]}]}]},{"type":"PRIMARY","title":"Actual Postoperative Blood Loss Compared to Average and Maximum Blood Loss Predicated Preoperatively by the Operating Surgeon","description":"Predicted average/maximum blood loss minus actual blood loss for participants who had a drain placed during surgery. Prior to the surgery, the surgeon will predict the estimated volume (mL) of the expected average and maximum blood loss for the planned surgical intervention in a hemostatically normal individual of the same sex, age, and stature as the study subject for the postoperative period until drain removal.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-221.4","spread":"331.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147.1","spread":"330.1"}]}]}]},{"type":"PRIMARY","title":"Daily Weight-Adjusted Dose of BAX326 Per Participant","description":"Daily weight-adjusted doses of BAX326 per participant were recorded from the day of surgery until postoperative Days 11+. Each category in outcome measure includes number of all, major and minor surgeries, respectively, if different from the totals.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144.8","spread":"70.3"},{"groupId":"OG001","value":"191.5","spread":"50.6"},{"groupId":"OG002","value":"87.2","spread":"42.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.9","spread":"44.6"},{"groupId":"OG001","value":"136.7","spread":"30.1"},{"groupId":"OG002","value":"63.5","spread":"18.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115.0","spread":"40.2"},{"groupId":"OG001","value":"134.2","spread":"27.6"},{"groupId":"OG002","value":"64.6","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.6","spread":"43.9"},{"groupId":"OG001","value":"123.5","spread":"39.4"},{"groupId":"OG002","value":"61.6","spread":"20.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"115.2","spread":"63.0"},{"groupId":"OG001","value":"123.5","spread":"62.4"},{"groupId":"OG002","value":"56.9","spread":"29.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.4","spread":"47.4"},{"groupId":"OG001","value":"108.6","spread":"46.6"},{"groupId":"OG002","value":"60.4","spread":"41.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105.6","spread":"44.0"},{"groupId":"OG001","value":"106.6","spread":"44.9"},{"groupId":"OG002","value":"86.0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":"46.7"},{"groupId":"OG001","value":"96.1","spread":"47.4"},{"groupId":"OG002","value":"65.5","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0","spread":"45.8"},{"groupId":"OG001","value":"93.0","spread":"45.8"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0","spread":"46.9"},{"groupId":"OG001","value":"93.0","spread":"46.9"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":"49.7"},{"groupId":"OG001","value":"89.9","spread":"49.7"},{"groupId":"OG002","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.3","spread":"44.8"},{"groupId":"OG001","value":"75.3","spread":"44.8"},{"groupId":"OG002","value":"0","spread":"0"}]}]}]},{"type":"PRIMARY","title":"Total Weight-Adjusted Dose of BAX326 Per Participant","description":"Assessed for the intra- and postoperative periods.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":"70"},{"groupId":"OG001","value":"191","spread":"51"},{"groupId":"OG002","value":"87","spread":"43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"808","spread":"766"},{"groupId":"OG001","value":"1350","spread":"617"},{"groupId":"OG002","value":"138","spread":"136"}]}]}]},{"type":"PRIMARY","title":"Number of Units of Blood Product Transfused","description":"Blood product transfusions consisted of packed red blood cells (PRBC) or fresh frozen plasma (FFP) or both.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"0.7"}]}]}]},{"type":"PRIMARY","title":"Volume of Blood Product Transfused","description":"Blood product transfusions consisted of packed red blood cells (PRBC) or fresh frozen plasma (FFP) or both.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"834.3","spread":"358.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"414.0","spread":"227.7"}]}]}]},{"type":"PRIMARY","title":"Safety: Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety: Number of Participants Who Developed Total Binding Antibodies to Factor IX (FIX)","description":"If there was more than 2-dilution increase as compared to pre-study level at screening.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety: Number of Adverse Events Related to BAX326","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Safety: Occurence of a Thrombotic Event","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) From 0 to 72 Hours Post-infusion Per Dose","description":"AUC0-72h (area under the plasma concentration/time curve from time 0 to 72 hours) was computed using the linear trapezoidal method. The concentration at 72 hours was interpolated from the two nearest sampling time points or extrapolated using the last quantifiable concentration and the terminal rate constant λz. λz was estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R2.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.48","spread":"6.43"}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Total Area Under the Plasma Concentration Versus Time Curve Per Dose (Total AUC/Dose)","description":"Total AUC/Dose is also AUC0-inf (area under the plasma concentration/time curve from time 0 to infinity) and was defined as AUC0-t + Ct / λz, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration and λz is the terminal rate constant.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.60","spread":"7.32"}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Mean Residence Time (MRT)","description":"The MRT is the average time that the study product stays in the body (or plasma) and is calculated as: AUMC 0-inf / AUC 0-inf, where AUMC 0-inf was determined in a similar manner as AUC 0-inf.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.17","spread":"4.03"}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Factor IX (FIX) Clearance (CL)","description":"CL is the volume of plasma which is completely cleared of study product per unit time and is calculated as the dose divided by the total area under the curve from 0 to infinity (AUC0-inf).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0523","spread":"0.0126"}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Incremental Recovery (IR) at 30 Min","description":"IR was defined as (C post-infusion - C pre-infusion) / Dose, where C post-infusion is the measured concentration achieved at 30±5 minutes for pre-surgical PK.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.29"}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Elimination Phase Half-life (T 1/2)","description":"T1/2 was determined as ln2 / λz.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.60","spread":"3.60"}]}]}]},{"type":"PRIMARY","title":"Pre-Surgical Pharmacokinetics (PK): Volume of Distribution at Steady State (Vss)","description":"Vss was computed as CL·MRT.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.41","spread":"0.38"}]}]}]},{"type":"PRIMARY","title":"Incremental Recovery (IR) at 15±5 Minutes Following Loading Dose Prior to Surgery","description":"IR was defined as (C post-infusion - C pre-infusion) / Dose, where C post-infusion is the measured concentration achieved at 15±5 minutes for the loading dose.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.910","spread":"0.1787"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Procedural pain","Thrombocytosis","Post procedural swelling","Haemorrhagic anaemia"]}}}